updated 8/31/2006 6:33:07 PM ET 2006-08-31T22:33:07

A federal judge blocked sales of a generic version of blood thinner Plavix on Thursday, finding it unlikely that its maker, a Canadian company, could prove that the patent on the drug used by 48 million Americans was invalid.

  1. Don't miss these Health stories
    1. Splash News
      More women opting for preventive mastectomy - but should they be?

      Rates of women who are opting for preventive mastectomies, such as Angeline Jolie, have increased by an estimated 50 percent in recent years, experts say. But many doctors are puzzled because the operation doesn't carry a 100 percent guarantee, it's major surgery -- and women have other options, from a once-a-day pill to careful monitoring.

    2. Larry Page's damaged vocal cords: Treatment comes with trade-offs
    3. Report questioning salt guidelines riles heart experts
    4. CDC: 2012 was deadliest year for West Nile in US
    5. What stresses moms most? Themselves, survey says

U.S. District Judge Sidney H. Stein in Manhattan issued his written ruling Thursday after a two-day hearing in which Sanofi-Aventis and partner Bristol-Myers Squibb Co. insisted the Canadian company, Apotex Inc., must be forced to stop selling its product.

The judge also denied demands by the companies that Apotex be forced to remove from the market the generic product it had already distributed.

Bristol-Myers shares jumped $1.75, or 8 percent, to $23.50 in extended trading on the New York Stock Exchange. The ruling was issued after the close of regular trading.

U.S. shares of Sanofi-Aventis, which is based in France, rose $1.55, or 3.4 percent, to $44.95 on the NYSE.

The judge said Sanofi-Aventis had adequately demonstrated that questions Apotex raised as to the validity and enforceability of its patent were without substantial merit.

He said he also concluded Sanofi-Aventis would suffer irreparable harm if Apotex were permitted to continue distributing its generic product and Apotex’s hardships primarily result from the company’s own calculated risk-taking.

The judge also considered the public interest of permitting competition to continue, noting that a large number of Americans have seen a significant cost savings since Apotex entered the market.

“Although there are competing — and substantial — public interests at stake on both sides of this litigation, the balance of those competing public interests slightly favors Sanofi,” the judge wrote. “The public interest in lower-priced drugs is balanced by a significant public interest in encouraging the massive investment in research and development that is required before a new drug can be developed and brought to market.”

Apotex had argued that a patent protecting sales of Plavix from competitors was no longer valid and that it was in the public interest to permit sales of its generic version of the drug because lower prices mean even more people can use a lifesaving drug.

An Apotex spokesman didn’t immediately return a telephone message for comment after Thursday’s ruling.

The Ontario-based Apotex began selling its product Aug. 8 after negotiations among the three companies failed to settle the dispute.

The judge said he based his decision on the chances that Apotex could ultimately prove it is entitled to sell its generic drug; the level of irreparable harm each side might suffer; the balance of hardships; and the impact on the public.

Bristol-Myers disclosed last month that the Department of Justice was investigating a deal in which Bristol-Myers and Sanofi-Aventis agreed to pay Apotex at least $40 million to keep its version of Plavix off the market until 2011. The deal was rejected by state attorneys general.

At the hearing before Stein, attorney Evan Chesler of Sanofi-Aventis said that allowing Apotex to flood the market with its product and force prices lower would cripple the spirit of drug innovators, jeopardizing future pioneering medical breakthroughs.

“You can never put this Humpty-Dumpty back together if it’s not stopped,” Chesler said.

Chesler did not immediately return a telephone call for comment Thursday.

Frank Allen Bernatowicz, an accountant, testified for Apotex that the company stood to lose up to $4 billion in costs, future sales and lost opportunity if it was forced to withdraw its drug from the marketplace.

He said Sanofi-Aventis and Bristol-Myers stood to lose half as much and could withstand the hit much easier because they were much larger than Apotex, a company with $1 billion in annual sales.

© 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments